4D Molecular Therapeutics Overview
4D Molecular Therapeutics Target Price
See 4D Molecular Therapeutics's analyst price targets ($33) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$10.26
Average Target Price
$33.00
221.6% upside
221.6% upside1 analysts in the last 4 months
High: $33 | Low: $33
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-08 | Goldman Sachs | $33 | 221.6% upside |  |
| 2025-11-11 | BarclaysGena Wang | $33 | 221.6% upside | |
| 2025-10-31 | Leerink PartnersMani Foroohar | $17 | 65.7% upside | |
| 2025-10-21 | RBC CapitalLisa Walter | $26 | 153.4% upside | |
| 2025-01-11 | Morgan StanleyJudah Frommer | $6 |  41.5% downside | |
| 2024-09-19 | BMO CapitalKostas Biliouris | $40 | 289.9% upside | |
| 2024-09-19 | Loop Capital MarketsGeulah Livshits | $39 | 280.1% upside | |
| 2024-09-19 | H.C. WainwrightMatthew Caufield | $36 | 250.9% upside | |
| 2024-04-15 | RBC CapitalLisa Walter | $40 | 289.9% upside | |
| 2024-04-15 | BarclaysGena Wang | $45 | 338.6% upside | |
| 2024-04-01 | JefferiesNalin Tejavibulya | $58 | 465.3% upside | |
| 2024-03-28 | BMO CapitalKostas Biliouris | $63 | 514% upside | |
| 2024-02-06 | BMO CapitalKostas Biliouris | $70 | 582.3% upside | |
| 2023-07-05 | Chardan CapitalGeulah Livshits | $30 | 192.4% upside | |
| 2022-11-18 | H.C. Wainwright | $36 | 250.9% upside | |
| 2022-04-05 | Evercore ISIJosh Schimmer | $40 | 289.9% upside | |